Flogenzyme pills, 100pcs

Composition

1 tablet, coated with an enteric coating, contains:

Active ingredients:

bromelain 450 U (FIP),

trypsin 1440 U (FIP) (24 µkat),

rutin (rutoside) 100 mg;

Auxiliary substances:

lactose monohydrate-148.58 mg;

corn starch-24 mg;

magnesium stearate-12.72 mg;

stearic acid-11.28 mg;

purified water-6.6 mg;

colloidal silicon dioxide-6.36 mg;

talc — 2.46 mg;

Shell:

methacrylic acid and methyl methacrylate copolymer (1: 1) is 11,89 mg;

macrogol 6000 — 0,67 mg;

talc — of 4.08 mg;

triethylcitrate — 1.2 mg;

vanillin — 0.15 mg

Pharmacological action

PHLOGENZYM is a drug of new generation, consisting of a combination of highly active proteolytic enzymes (enzymes) of plant and animal origin, bromelain and trypsin in combination with rutin. In combination, the enzymes have a pleiotropic (multiple) effect, having a variety of pharmacological effects on pathophysiological and biochemical processes.

Enzymes of the drug realize their therapeutic effects through anti-inflammatory, immunomodulatory, antiplatelet, fibrinolytic, thrombolytic, decongestant and secondary analgesic actions. Tablets of the drug, coated with an enteric coating, transitorly pass through the upper gastrointestinal tract without injuring the stomach, are absorbed in the small intestine by resorption of intact molecules (endocytosis, pinocytosis).

Proteases of the drug bind to blood transport proteins (α-2-macroglobulin and α-1-antitrypsin) and form a reversible protease-antiprotease complex, which masks the antigenic determinants of exogenous proteases of the drug, which prevents allergic reactions. As a result of the formation of a complex with enzymes, antiprotease (α-2-macroglobulin) passes into the active form, which serves as an extracellular regulator of pro-inflammatory cytokines and growth factors, carrying out their transfer, clearance and elimination.

The formation of an active protease-antiprotease complex allows you to safely move proteolytic enzymes along the vascular bed to the focus of inflammation and to the site of injury, regardless of the location in the body.

The complex retains and slows down the elimination of proteolytic enzymes of the drug from the body, increases the time of their circulation in the vascular bed and, accordingly, the therapeutic effect. Once in the focus of inflammation and wounds, proteolytic enzymes break down (hydrolyze) damaged proteins and tissues and eliminate (remove) cellular debris (detritus), helping to accelerate the cleansing and healing of the wound.

The drug has a positive effect on the course of the inflammatory process, modulates the body’s protective reactions, which contributes to the physiological course of inflammation at different stages. Proteolytic enzymes of the drug accelerate the breakdown of inflammatory mediators, break down immune complexes and membrane deposits, increase the activity of phagocytes, natural killer cells, and stimulate interferogenesis.

Proteases of the drug reduce the level of pro-inflammatory cytokines (IL-1b, IL-6, IL-8, INF-γ, TNF-α) and increase the production of anti-inflammatory cytokines (including IL-4, IL-10), regulate the level of Ig and blood antibodies. Enzymes of the drug limit the pathological manifestations of autoimmune and immunocomplex processes, restore the immunological reactivity of the body.

Proteases of the drug reduce the level of transforming growth factor β, an increase in which leads to excessive scarring. Proteolytic enzymes have a regulatory effect on the synchronization of basal membrane formation (laminin), modulation of the wound process, and expression of angiogenesis factors (vasculoendothelial growth factor, fibroblast growth factor, and a number of other factors). Thus, the enzymes of the drug contribute to improving reparative processes, preventing the formation of hypertrophic and keloid scars, and the development of adhesive disease after surgical interventions on the abdominal cavity.

Enzymes of the drug break down and remove damaged tissues, accelerate the resorption of hematomas and edema by normalizing the permeability of vascular walls, reducing interstitial infiltration with plasma proteins, increasing the elimination of protein detritus and fibrin deposits, improving microcirculation and trophic processes in the damaged area.

Optimization of the inflammatory process by proteolytic enzymes by reducing oncotic pressure and tissue edema, reducing pressure on nerve endings, eliminating ischemia and normalizing microcirculation, and direct proteolysis of inflammatory mediators allows proteases to have a secondary analgesic effect. At the same time, proteolytic enzymes stimulate the healing and repair processes, reduce the risk of thromboembolic complications during prolonged immobilization, and prevent the development of trophic disorders and purulent complications.

Enzymes of the drug have a positive effect on improving microcirculation, increasing the delivery of oxygen and nutrients to the wound, reducing inflammation in the lesion, maintaining the physiological regeneration process and accelerating the restoration of organ and tissue function.

The drug improves the rheological properties of blood (viscosity and fluidity) due to a positive effect on the functional state of blood cells and the vascular wall, plasticity (deformability) of red blood cells, stabilization of endothelial permeability, increased fibrinolytic activity of blood serum, reduced density of adhesive molecules, reduced aggregation (sticking) of platelets.

Proteolytic enzymes reduce the number of activated forms of platelets (spheroechinocytes) and micro-and macroaggregates, thus reducing the risk of thrombosis in blood vessels, and simultaneously participate in the lysis of formed blood clots. Proteolytic enzymes reduce the level of atherogenic lipids, contributing to an increase in HDL, reducing the risk of developing atherosclerosis and vascular disorders.

The drug improves blood supply to the bronchi and lung tissue in chronic respiratory diseases, including those caused by smoking, improves the viscosity properties of bronchial secretions, the function of the ciliated epithelium, restores the drainage function of the bronchi, dilutes sputum, which facilitates breathing and reduces cough.

Proteolytic enzymes of the drug increase the effectiveness of antibiotics, while reducing the undesirable effects of antibiotic therapy (dysbiosis, irritable bowel syndrome). Proteases improve the cleavage of substrates, optimize the balance of the microbiota, and promote the restoration of intestinal endoecology.

Indications

In complex therapy and prevention of the following diseases and conditions:

• surgery — postoperative recovery and rehabilitation of patients (improvement of reparative processes and regeneration), postoperative purulent-inflammatory complications, prevention of the development of adhesive disease and keloid scar, reducing the risk of thromboembolic complications during prolonged immobilization;
• trauma — fractures, injuries to tendons and ligaments, contusions and hematoma of soft tissue sports injuries, burns, improve the integration of implants, osteosynthesis;
• angiology acute deep venous thrombosis, thrombophlebitis of superficial veins, post-thrombotic syndrome, atherosclerosis obliterans of lower limb arteries and other chronic angiopathy, disturbance of microcirculation, lymphatic swelling (lymphedema);
• urology acute and chronic inflammation of the urinary tract (cystitis, urethritis, cystopyelitis, prostatitis);
• gynecology, acute and chronic inflammatory diseases of the pelvic organs (adnexitis, oophoritis), vascular complications of menopause, the reduction in the frequency and severity of complications of hormone replacement therapy;
• cardiology — coronary heart disease, prevention of angina attacks, reduce the risk of vascular accidents and repeated heart attacks;
• gastroenterology hepatitis;
• rheumatology — rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, rheumatic soft tissue;
• neurology ischemic stroke, multiple sclerosis;
• pulmonology — pneumonia, chronic obstructive pulmonary disease;
• dentistry — prevention of complications in the postoperative period in the extraction of teeth, inflammatory diseases of the maxillofacial region, rehabilitation and recovery after surgical interventions in the maxillofacial region, to improve the integration of implants, osteosynthesis.

Contraindications

• individual intolerance to the components of the drug;
• congenital or acquired blood clotting disorders;
• childhood.

With caution: performing hemodialysis (after consulting a doctor).

Side effects

The drug is well tolerated by patients. In some cases, there may be frequent stools, changes in the consistency and smell of the stool, which are quickly stopped with a temporary decrease in the dosage of the drug.

Occasionally, an allergic reaction (skin rash, itching) may occur, which disappears after reducing the dose or discontinuing the drug. If the conditions of use of the drug are violated, nausea, bloating and abdominal pain, headache, dizziness, exanthema, general weakness, and a feeling of intestinal overcrowding may occur.

These conditions disappear after reducing the dosage or temporarily discontinuing the drug.

Interaction

There were no cases of incompatibility with other drugs.

The use of the drug together with antibiotics increases the effectiveness of antibiotic therapy.

When used with hormones, the drug reduces the risk of blood clots.

How to take, course of use and dosage

Inside.

Take at least 30 minutes before meals, without biting, with water (200 ml). After surgery, the drug is recommended to be taken from the 2nd-3rd day.

Treatment. The drug is taken after injuries and operations or acute inflammation to split and remove damaged tissues, resolve hematomas, improve tissue trophism and reparative processes, reduce inflammation and edema, reduce the risk of complications — thrombosis, development of adhesive disease, keloid scar formation and wound suppuration: 3 tablets 3 times a day for 2 weeks. If necessary, to improve recovery and healing, the course of taking the drug can be extended to 4 weeks or more,2 tablets 3 times a day.

Prevention of complications. To prevent long-term consequences after surgery-thromboembolic complications, the development of abdominal adhesions, trophic disorders during prolonged bed rest and immobilization of the patient: the drug is recommended to take a long course in a dosage of 2 tablets 3 times a day for 4 weeks or more or for the entire period of immobilization.

Use with antibiotics. When prescribing antibiotics, the drug is used to increase the effectiveness of antibiotic therapy and reduce the undesirable effects of antibiotics. The drug is recommended to take 2 tablets 3 times a day during the entire course of antibiotic therapy.

Use with hormones. When prescribing long-term courses of hormones, the drug is recommended to be taken to reduce the risk of complications (thrombosis),2 tablets 3 times a day during the entire course of taking hormonal drugs. When prescribing hormone replacement therapy to reduce the risk of venous thrombosis of the lower extremities, the drug is recommended to take 2 tablets 3 times a day in repeated courses of 2 weeks with breaks of 3 weeks 3-4 times a year.

Prevention. To prevent venous thrombosis of the lower extremities and reduce the risk of vascular accidents (heart attack), the drug is recommended to take 2 tablets 3 times a day for at least 3-4 weeks, repeating the courses of taking the drug 3-4 times a year.

Changing the course and dosage of the drug is recommended after consultation with your doctor.

Special instructions

In the case of infectious processes, PHLOGENZYME does not replace antibiotics.

In case of exacerbation of the underlying disease while taking the drug, it is recommended to temporarily reduce the dose of the drug or temporarily cancel the drug after consulting a doctor.

Patients with diabetes should note that each tablet of the drug contains 0.015 XE.

Influence on the ability to drive a car or perform work that requires an increased rate of physical and mental reactions. The drug is not doping, does not have a negative impact on driving a car and performing work that requires a high speed of mental and physical reactions.

Form of production

Enteric coated tablets

Storage conditions

In a dry place, at a temperature of 15-25 °C

Shelf life

3 years

Active ingredient

Trypsin, Rutoside, Bromelain

Dosage form

Tablets

Purpose

Children as prescribed by a doctor, For adults, Pregnant women as prescribed by a doctor

Indications

Urethritis, Chronic obstructive pulmonary disease, Swelling after injuries and operations, Thrombophlebitis, Burns, Hepatitis, Rheumatoid arthritis